BioLargo reported FY 2025 revenue of USD 7.8 million, down 56% year over year, reflecting a 66% decline in product sales to USD 5.8 million that the company said was almost entirely due to lower private-label volumes for its largest customer, Pooph. Services revenue rose 96% to USD 2.0 million on additional engineering consulting contracts. BioLargo posted a FY 2025 net loss of USD 15.2 million (USD 0.04 per share), and recorded USD 3.8 million of credit loss expense tied to amounts owed by Pooph that management determined were fully impaired during Q3 2025. Cash and cash equivalents were USD 3.9 million at Dec. 31, 2025; BioLargo used USD 8.3 million of cash in operations in FY 2025 and ended the year with working capital of USD 0.05 million. In business updates, the ONM Environmental segment reported FY 2025 revenue of USD 5.9 million, down 62%, and an operating loss of USD 2.3 million, driven by reduced Pooph-related volumes and credit losses. BioLargo and ONM filed a lawsuit against Pooph in November 2025 alleging patent infringement, false advertising and breach of contract, among other claims, seeking damages including USD 1.7 million in unpaid royalties and USD 2.2 million for unpaid product purchases; Pooph also filed a separate lawsuit against ONM alleging breach of contract. The BLEST engineering division generated FY 2025 third-party service revenue of USD 2.0 million, up 96%, citing increased work for existing and new clients including U.S. Air Force bases. Clyra Medical reported no revenue in FY 2025 and FY 2024, and said it received its first purchase order for its ViaCLYR product in February 2026, expecting to record revenue in the three months ending March 31, 2026. BioLargo said the factors described raise substantial doubt about its ability to continue as a going concern without additional financing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLargo Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-006926), on March 04, 2026, and is solely responsible for the information contained therein.
Comments